125 related articles for article (PubMed ID: 36657293)
21. Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer.
Liu K; Graves JD; Lin FT; Lin WC
J Biol Chem; 2021; 296():100382. PubMed ID: 33556369
[TBL] [Abstract][Full Text] [Related]
22. Insulin-like Growth Factor 1 Receptor Signaling Is Required for Optimal ATR-CHK1 Kinase Signaling in Ultraviolet B (UVB)-irradiated Human Keratinocytes.
Kemp MG; Spandau DF; Simman R; Travers JB
J Biol Chem; 2017 Jan; 292(4):1231-1239. PubMed ID: 27979966
[TBL] [Abstract][Full Text] [Related]
23. Targeting DNA damage response pathways to activate the STING innate immune signaling pathway in human cancer cells.
Wayne J; Brooks T; Landras A; Massey AJ
FEBS J; 2021 Aug; 288(15):4507-4540. PubMed ID: 33529438
[TBL] [Abstract][Full Text] [Related]
24. Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.
Furusawa Y; Iizumi T; Fujiwara Y; Hassan MA; Tabuchi Y; Nomura T; Kondo T
Ultrason Sonochem; 2012 Nov; 19(6):1246-51. PubMed ID: 22571845
[TBL] [Abstract][Full Text] [Related]
25. PNAS-4, an Early DNA Damage Response Gene, Induces S Phase Arrest and Apoptosis by Activating Checkpoint Kinases in Lung Cancer Cells.
Yuan Z; Guo W; Yang J; Li L; Wang M; Lei Y; Wan Y; Zhao X; Luo N; Cheng P; Liu X; Nie C; Peng Y; Tong A; Wei Y
J Biol Chem; 2015 Jun; 290(24):14927-44. PubMed ID: 25918161
[TBL] [Abstract][Full Text] [Related]
26. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
27. Imatinib inhibits inactivation of the ATM/ATR signaling pathway and recovery from adriamycin/doxorubicin-induced DNA damage checkpoint arrest.
Morii M; Fukumoto Y; Kubota S; Yamaguchi N; Nakayama Y; Yamaguchi N
Cell Biol Int; 2015 Aug; 39(8):923-32. PubMed ID: 25790472
[TBL] [Abstract][Full Text] [Related]
28. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis.
Pabla N; Huang S; Mi QS; Daniel R; Dong Z
J Biol Chem; 2008 Mar; 283(10):6572-83. PubMed ID: 18162465
[TBL] [Abstract][Full Text] [Related]
29. High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells.
Jia R; Kutzner L; Koren A; Runggatscher K; Májek P; Müller AC; Schuster M; Bock C; Loizou JI; Kubicek S; Kralovics R
Blood Cancer J; 2021 Jul; 11(7):137. PubMed ID: 34333533
[TBL] [Abstract][Full Text] [Related]
30. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
[TBL] [Abstract][Full Text] [Related]
31. Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors.
Wang WT; Catto JW; Meuth M
Oncogene; 2015 May; 34(22):2887-96. PubMed ID: 25043304
[TBL] [Abstract][Full Text] [Related]
32. Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer.
Meyer F; Becker S; Classen S; Parplys AC; Mansour WY; Riepen B; Timm S; Ruebe C; Jasin M; Wikman H; Petersen C; Rothkamm K; Borgmann K
Cells; 2020 Jan; 9(1):. PubMed ID: 31963582
[TBL] [Abstract][Full Text] [Related]
33. ACTL6A deficiency induces apoptosis through impairing DNA replication and inhibiting the ATR-Chk1 signaling in glioblastoma cells.
Hu X; Pei D; Ci M; Zhang G; Li B; Wang J; Shen Y; Zhai X; Liang P; Cui H
Biochem Biophys Res Commun; 2022 Apr; 599():148-155. PubMed ID: 35182941
[TBL] [Abstract][Full Text] [Related]
34. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ
Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113
[TBL] [Abstract][Full Text] [Related]
35. Involvement of Host ATR-CHK1 Pathway in Hepatitis B Virus Covalently Closed Circular DNA Formation.
Luo J; Luckenbaugh L; Hu H; Yan Z; Gao L; Hu J
mBio; 2020 Feb; 11(1):. PubMed ID: 32071277
[TBL] [Abstract][Full Text] [Related]
36. DNA-PKcs is required to maintain stability of Chk1 and Claspin for optimal replication stress response.
Lin YF; Shih HY; Shang Z; Matsunaga S; Chen BP
Nucleic Acids Res; 2014 Apr; 42(7):4463-73. PubMed ID: 24500207
[TBL] [Abstract][Full Text] [Related]
37. ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and And-1.
Moiseeva T; Hood B; Schamus S; O'Connor MJ; Conrads TP; Bakkenist CJ
Nat Commun; 2017 Nov; 8(1):1392. PubMed ID: 29123096
[TBL] [Abstract][Full Text] [Related]
38. ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias.
Boudny M; Trbusek M
Cancer Treat Rev; 2020 Aug; 88():102026. PubMed ID: 32592909
[TBL] [Abstract][Full Text] [Related]
39. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
Gralewska P; Gajek A; Marczak A; Rogalska A
J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
[TBL] [Abstract][Full Text] [Related]
40. Src family kinases promote silencing of ATR-Chk1 signaling in termination of DNA damage checkpoint.
Fukumoto Y; Morii M; Miura T; Kubota S; Ishibashi K; Honda T; Okamoto A; Yamaguchi N; Iwama A; Nakayama Y; Yamaguchi N
J Biol Chem; 2014 May; 289(18):12313-29. PubMed ID: 24634213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]